Windtree Therapeutics Announces Sale of Cardiovascular Assets to Seismic

What Happened
Windtree Therapeutics, Inc. (WINT) filed an 8-K on July 22, 2026 reporting it entered a material definitive agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC (SPO). Under the agreement (dated December 16, 2025), Windtree is entitled to 20% of any future proceeds SPO receives related to those assets, including global commercial net revenue in acute heart failure (AHF) if the product is approved by regulators.

Key Details

• Agreement date: December 16, 2025; 8‑K filed July 22, 2026.
• Windtree will receive 20% of any future proceeds received by SPO (including potential global commercial net revenue in AHF if approved).
• If SPO completes a financing of at least $10 million to develop the assets, Windtree will receive a $700,000 payment from those proceeds.
• Windtree will transfer certain cardiovascular drug development payables to SPO as part of the transaction.
• Exhibits filed with the 8‑K include the Asset Purchase Agreement and a related press release (Dec 2025).

Why It Matters
For investors, the deal shifts development responsibility and related payables to SPO while preserving a stake in future upside through a 20% proceeds interest. The arrangement could reduce Windtree’s near‑term cash burn and liabilities but does not guarantee immediate material cash proceeds beyond the contingent $700,000 tied to SPO securing at least $10 million in financing. Future value to Windtree depends on SPO’s development progress, financing, regulatory approvals, and eventual commercialization outcomes.